Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Phase 1: Advanced or Refractory Solid Tumours|Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer
Interventions: DRUG: LiPlaCis
Sponsor: Allarity Therapeutics